Pharmacoeconomic considerations in the health system management of anaemia in patients with chronic kidney disease and end stage renal disease

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 9, 2003, Pages 1461-1469

  Brophy, Donald F ^a   Ripley, Elizabeth B D ^a   Holdford, David A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anaemia; Chronic kidney disease; Darbepoetin; End stage renal disease; Epoetin; Pharmacoeconomics

Indexed keywords

BENZYL ALCOHOL; CARNITINE; CITRIC ACID; HEMOGLOBIN; IRON; NANDROLONE DECANOATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ACNE; ANEMIA; BIOTECHNOLOGY; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; ERECTILE DYSFUNCTION; ERYTHROPOIESIS; FUNCTIONAL ASSESSMENT; GOVERNMENT; GYNECOMASTIA; HEALTH CARE SYSTEM; HEMOGLOBIN DETERMINATION; HOSPITAL PATIENT; HUMAN; INJECTION PAIN; KIDNEY FAILURE; MEDICAL DECISION MAKING; OUTPATIENT CARE; PREVALENCE; QUALITY OF LIFE; REIMBURSEMENT; REVIEW; SURVIVAL;

ANEMIA; ERYTHROPOIETIN; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; PRACTICE GUIDELINES;

EID: 0141628415     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.9.1461     Document Type: Review

References (57)

1. JONES CA, MCQUILLAN GM, KUSEK JW et al.: Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. Am. J. Kidney Dis. (1998) 32:992-999. [Erratum in Am. J. Kidney Dis. (2000) 35:178].
2. USRDS 2001 Annual Data Report, Bethesda, MD, USA. National Institutes of Health, National institutes of Diabetes and Digestive and Kidney Diseases (2001).
3. EVANS RW: Recombinant human erythropoietin and the quality of life of end-stage renal disease patients: a comparative analysis. Am. J. Kidney Dis. (1991) 18(4 Suppl. 1):62-70.
4. KEOWN PA: Quality of life in end-stage renal disease patients during recombinant human erythropoietin therapy. The Canadian Erythropoietin Study Group. Contrib. Nephrol. (1991) 88:81-86.
5. MORENO F. SANZ-GUAJARDO D, LOPEZ-GOMEZ JM, JOFRE R, VALDERRABANO F: Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J. Am. Soc. Nephrol. (2000) 11(2):335-342.
6. WOLCOTT DL, MARSH JT, LA RUE A, CARR C, NISSENSON AR: Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am. J. Kidney Dis. (1989) 14(6):478-485.
7. DELANO BG: Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am. J. Kidney Dis. (1989) 14(2 Suppl. 1):14-18.
8. RAVICKI DA, BROWN RE, FEENY DH et al.: Health-Quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am. J. Kidney Dis. (1995) 25(4):548-554.
9. FOLEY RN, PARFREY PS, HARNETT JD, KENT GM, MURRAY DC, BARRE PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am. J. Kidney Dis. (1996) 28(1):53-61.
10. HARNETT JD, FOLEY RN, KENT GM, BARRE PE, MURRAY D, PARFREY PS: Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int. (1995) 47(3):884-890.
11. CANNELLA G, LA CANNA G, SANDRINI M et al.: Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients. Clin. Nephrol. (1990) 34(6):272-278.
12. AL-AHMAD A, RAND WM, MANJUNATH GM et al.: Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J. Am. Coll. Cardiol. (2002) 39(10):1703-1704.
13. VEYS N, VANHOLDER R, RINGOIR S: Correction of deficient phagocytosis during erythropoietin treatment in maintenance hemodialysis patients. Am. J. Kidney Dis. (1992) 19(4):358-363.
14. GAFTER U, KALECHMAN Y, ORLIN JB, SREDNI B: Anemia of uremia is associated with reduced in vitro cytokine secretion: immunopotentiating activity of red blood cells. Kidney Int. (1994) 45(1):224-231.
15. PALMER BF: Sexual dysfunction in men and women with chronic kidney disease and end-stage kidney disease. Adv. Ren. Replace. Ther. (2003) 10(1):48-60.
16. PALMER BF: Sexual dysfunction in uremia. J. Am. Soc. Nephrol. (1999) 10(6):1381-1388.
17. LEAVEY SF, WEITZEL WF: Endocrine abnormalities in chronic renal failure. Endocrinol. Metab. Clin. North Am. (2002) 31(1):107-119.
18. RAMIREZ G, BITTLE PA, SANDERS H, RABB HA, BERCU BB: The effects of corticotropin and growth hormone releasing hormones on their respective secretory axes in chronic hemodialysis patients before and after correction of anemia with recombinant human erythropoietin. J. Clin. Endocrinol. Metab. (1994) 78(1):63-69.
19. BURKE JR: Low-dose subcutaneous recombinant erythropoietin in children with chronic renal failure. Australian and New Zealand Paediatric Nephrology Association. Pediatr. Nephrol. (1995) 9(5):558-561.
20. KAUSZ AT, KHAN SS, ABICHANDANI R et al.: Management of patients with chronic renal insufficiency in the northeastern United States. J. Am. Soc. Nephrol. (2001) 12(7):1501-1507.
21. US RENAL DATA SYSTEM: USRDS 2002 Annual data report: adas of end-stage. Renal disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA (2002).
22. VALDERRABANO F, HORL WH, JACOBS C et al.: European Best Practice Guidelines 1-4: evaluating anaemia and initiating treatment. Nephrol. Dial. Transplant. (2000) 15(Suppl. 4):S8-S14.
23. CARO J, BROWN S, MILLER O, MURRAY T, ERSLEV AJ: Erythropoietin levels in uremic nephric and anephric patients. J. Lab. Clin. Med. (1979) 93:449-458.
24. ESCHBACH JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int. (1989) 35(1):134-148.
25. AGARWAL R, WARNOCK D: Issues related to iron replacement in chronic kidney disease. Semin. Nephrol. (2002) 22(6):479-87.
26. SANTORO A: Anemia in renal insufficiency. Rev. Clin. Exp. Hematol, (2002) (Suppl.1):12-20.
27. NATIONAL KIDNEY FOUNDATION: K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am. J. Kidney Dis. (2001) 37(Suppl. 1):S182-S238.
28. ANONYMOUS: Guideline 9. Route of administration of epoetin. Nephrol, Dial. Transplant. (1999) 14(Suppl. 5):S19-S20.
29. JOHNSON CA: Use of androgens in patients with renal failure. Semin. Dial. (2002) 13(1):36-39.
30. GOLPER TA, GORAL S, BECKER BN, LANGMAN CB: L-carnitine treatment of anemia. Am. J. Kidney Dis. (2003) 41(4 Suppl. 4):S27-S34.
31. TROVATO GM, GINARDI V, DI MARCO V, DELL'AIRA A, CORSI M: Long term L-carnitine treatment of chronic anemia of patients with end-stage renal failure. Curr. Ther. Res. (1982) 31:1042-1049.
32. NATIONAL KIDNEY FOUNDATION: K/DOQI Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. Am. J. Kidney Dis. (2000) 35(6 Suppl. 2):S1-S140.
33. WHITTINGTON R, BARRADELL LB, BENFIELD P: Epoetin. A pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life. Pharmacoeconomics (1993) 3(1):45-82.
34. HYNES DM, STROUPE KR, GREER JW et al.: Potential cost savings of erythropoietin administration in end-stage renal disease. Am. J. Med. (2002) 112:169-175.
35. LEESE B, MAYNARD A: A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries. Pharmacoeconomics (1992) 1(5):346-356.
36. MCNAMEE P, VAN DOORSLAER E, SEGAAR R: Benefits and costs of recombinant human erythropoietin for end-state renal disease. Int. J. Technol. Assess. Health Care (1993) 9(4):490-504.
37. SPENCE RK, CERNAIANU AC, CARSON J, DELROSSI AJ: Transfusion and surgery. Curr. Probl. Surg. (1993) 30:1101-1180.
38. CORWIN HL, GETTINGER A, PEARL RG et al.: Efficacy of recombinant human erythropoietin in critically ill patients. JAMA (2002) 288(22):2827-2835.
39. HEBERT PC, WELLS G, BLAJCHMAN MA et al.: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements In Critical Care Trials Group. N. Engl. J. Med. (1999) 340:409-417.
40. o BLUMBERG N, HEAL JM: Effects of transfusion on immune function: cancer recurrence and infection. Arch. Pathol. Lab. Med. (1994) 118:371-379.
41. GOODNOUGH LT, BRECHER ME, KANTER MH, AUBUCHON JP: Transfusion medicine: first of two partsblood transfusion. N. Engl. J. Med. (1999) 340:438-447.
42. MICKLER TA, LONGNECKER DE: The immunosuppressive aspects of blood transfusion. J. Intensive Care Med. (1992) 7:176-188.
43. LOCATELLI F, OLIVARES J, WALKER R: Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int. (2001) 60:741-747.
44. COLLINS AJ, MA JZ, EBBEN J: Impact of hematocrit on morbidity and mortality. Semin. Nephrol. (2000) 20(4):345-349.
45. OFSTHUN N, LABRECQUE J, LACSON E, KEEN M, LAZARUS JM: The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int. (2003) 63(5):1908-1914.
46. ALJAMA P, BOMMER J, CANAUD B et al.: Practical guidelines for the use of NESP in treating renal anaemia. Nephrol. Dial. Transplant. (2001) 16(Suppl. 3):S22-S28.
47. ASHAI NI, PAGANINI EP. WILSON JM: Intravenous versus subcutaneous dosing of epoetin: a review of the literature. Am. J. Kidney Dis. (1993) 22(Suppl. 1):S23-S31.
48. KAUFMAN JS, REDA DJ, FYE CL et al.: Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N. Engl. J. Med. (1998) 339:578-583.
49. KAUFMAN JS: Subcutaneous erythropoietin therapy: efficacy and economic implications. Am. J. Kidney Dis. (1998) 32(Suppl. 4):S127-S151.
50. BESARAB A, REYES CM, HORNBERGER J: Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am. J. Kidney Dis. (2002) 40(3):439-446.
51. HEALTH CARE FINANCING ADMINISTRATION. ANNUAL REPORT: Health care financing administration's end-stage renal disease core indicators project. department of health and human services, health care financing administration, office of clinical standards and quality: Baltimore, MD, USA (1998).
52. MCCLELLAN WM, FRANKENFIELD DL, WISH JB et al.: Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: results from the 1998 End-Stage Renal Disease Core Indicators Project. Am. J. Kidney Dis. (2001) 37:E36.
53. ST PETER WL, LEWIS MJ, MACRES MG: Pain comparison after subcutaneous administration of single-dose formulation versus multidose formulation of epogen in hemodialysis patients. Am. J. Kidney Dis. (1998) 32(3):470-474.
54. FRENKEN LAM, VAN LIER HJJ, JORDANS JGM et al.: Identification of the component part in an epoetin alfa preparation that causes pain after subcutaneous injection. Am. J. Kidney Dis. (1993) 22(4):553-556.
55. GRANOLLERAS C, LESKOPF W, SHALDON S, FOURCADE J: Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: a randomized, double-blind crossover study. Clin. Nephrol. (1991) 36:294-298.
56. NISSENSON AR: Dosing darbepoetin alfa. Am. J. Kidney Dis. (2002) 40(4):872-873 (Letter).
57. DERAY G: Dosing darbepoetin alfa continued. Am. J. Kidney Dis. (2003) 41(6):1334-1336 (Letter).